EGFR/EGFRvIII inhibitor CM93

{
  "id": "MLC-T-ONC-013273",
  "term": "EGFR/EGFRvIII inhibitor CM93",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, blood-brain-barrier (BBB) penetrable, third-generation, covalent inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including the EGFR variant III (EGFRvIII) mutant form, with potential antineoplastic activity. Upon oral administration, EGFR/EGFRvIII inhibitor CM93 specifically targets, irreversibly binds to and inhibits EGFR and specific EGFR mutations, which prevents EGFR/EGFR mutant-mediated signaling and leads to cell death in EGFR/EGFR mutant-expressing tumor cells. EGFR, a receptor tyrosine kinase (RTK) that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-egfrviii-inhibitor-cm93/"
}